As EGFR-TKI resistance in patients with EGFR-mutant NSCLC is one type of a “therapy-dependent” clinical condition, acquired resistance is defined as being progressive “while” receiving EGFR-TKI [9, 19]. Here, EGFR is linked to non-small cell lung carcinoma.